Earnings from Abbott Laboratories [ABT] are scheduled on April 20, 2021, before the market opens. It is expected that the company will report strong earnings for the quarter ending Mar 2021.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
ABT Stock Earnings Outlook For The Current Quarter
The consensus estimates for the quarter suggest that the company would earn $1.27 per share on revenue of $10.69B. Taking a look at the future, the company is projected to report revenue of $10.59B at an earnings per share of $1.26 for the Jun 2021 quarter. The estimates represent year-over-year improvements of -0.30% in revenue and 5.91% in earnings per share for the company.
ABT Stock Earnings Forecast For The Current Year
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
For the full financial year, Abbott Laboratories [NYSE:ABT] is forecasted to generate revenue of $42.19B. The figure is about $7.58 billion above what the company actually reported for the fiscal year 2020. In terms of EPS, it is estimated to be $5.04 in 2021, which is $1.39 higher than the figure in FY20. Based on current estimates, earnings are expected to grow 38.10% this year, 4.80% next year, and 15.58% annually over the next five years. With regard to sales, forecasts suggest an incline of 21.90% in current fiscal year and -0.30% over following year.
ABT Stock Price Performance
At the close of Monday’s session, Abbott Laboratories [NYSE:ABT] finished up 0.14% at $124.53. The stock’s highest single-day price was $125.42, and its lowest was $123.59. Its price rose 2.88% in the last five days. Since the beginning of the year, Abbott Laboratories’s shares are up nearly 13.74%. However, the share price is -3.12% below its one year high. The top price reached by the shares of the company was $128.54 on 02/12/21, while the 52-week low came on 01/04/21, when the shares were $107.26. In the past year, shares of the company have risen 29.71%. At 50 days, the moving average achieved is $121.15 while at 200 days, the moving average is $110.22. There were 6.85 million shares traded in the last session, up from 6.24 million in the previous session.
Abbott Laboratories [NYSE:ABT] Stock Valuation Metrics
With a prevailing 12-month PE ratio of 49.51, Abbott Laboratories [ABT] does not qualify as a good candidate for the list of underestimated low-priced stocks that should be purchased sooner rather than later. By this measure, the company’s stock is trading at a premium to the industry average of 36.41 times trailing earnings. Investors may find it helpful to look at historical price-sales ratios, and in the case of this stock, 6.35 PS value ratio is reported for the last one year of reported earnings. This is above the average return 5.84 for the industry, which means ABT offers an unattractive investment opportunity than its competitors do.
ABT Share Price Support And Resistance Levels
Based on the daily chart, the immediate backing lies around the 124.53 level, and the violation of this level will cause a further drop to 123.61 level. At the upper end, 127.27 remains a key resistance. As the stock increases, it may find resistance at 126.34. In the 14-day chart, the Relative Strength Index standing at 62.72 suggests a technical neutral stance while the MACD standing at 3.02 indicates price will increase in the next trading period. Stochastic %K at 89.49% suggests selling the stock while Percent R indicator at 13.40% suggests bullish price movement.
How much is the short interest in Abbott Laboratories?
There have been a drop in short interest in the Abbott Laboratories Financial stock, with short interest up by 3.85 million shares to 9.79 million shares on Feb 25, 2021. According to data provided by Yahoo Finance, the short interest on Mar 30, 2021 stood at 13.64 million shares. This -39.33% decrease suggests some bullish sentiment was experienced by the stock. Shorted shares accounted for just 0.79% of the overall float in the stock, while the stock’s days to cover moved to 2.61.
How do analysts view Abbott Laboratories?
In regard to the share price forecast for Abbott Laboratories stock, the analysts, as surveyed by FactSet, forecast the price to reach $137.00 in the next twelve months, representing almost an 9.1% growth from its recent price of $124.53. Among Abbott Laboratories stock projections, $158.00 is the highest analyst target for the stock, while $111.00 is the lowest. Despite this, 23 analysts who share their consensus rating for ABT in 2021 agree that the stock is an Overweight.